TRUMP’S BOLD MOVE: Marijuana Reclassified

President Trump’s bold executive order reclassifying marijuana from Schedule I to Schedule III delivers a pragmatic win for medical patients and states’ rights, but ignites fierce backlash from conservative lawmakers demanding a reversal.

Story Highlights

Trump’s December 2025 order expedites marijuana rescheduling, acknowledging medical uses after decades as a Schedule I drug equated with heroin.
Bipartisan roots: Process started under Biden, accelerated by Trump to cut tax burdens on state-legal businesses and boost research.
House Republicans, led by Rep. Pete Sessions, urge Trump to halt the move, citing high abuse potential.
Senate GOP senators file amendment to block rescheduling via funding bill, highlighting party divide.
Implementation underway in April 2026, promising relief for 40 medical states amid ongoing federal prohibition.

Trump’s Executive Action Cuts Through Bureaucratic Delay

President Donald Trump signed an executive order on December 18, 2025, directing the Attorney General to expedite marijuana’s reclassification from Schedule I to Schedule III. This shift recognizes credible medical evidence for treating pain, anorexia, and chemotherapy nausea, as affirmed by HHS, FDA, and NIDA. The move overrides stalled DEA hearings, fulfilling Trump’s promise at the signing: marijuana has legitimate medical uses. State-licensed dispensaries stand to gain tax deductions long denied under Schedule I rules. By April 2026, implementation advances, easing burdens on 40 states with medical programs and 24 with recreational laws.

Republican Lawmakers Push Back Against Federal Shift

House Republicans, led by Rep. Pete Sessions of Texas and Freedom Caucus Chairman Andy Harris of Maryland, sent a letter to Trump urging him to keep marijuana as Schedule I. They argue it belongs with heroin and LSD due to high abuse potential and no accepted medical use. Twenty-four GOP lawmakers joined, viewing reclassification as a dangerous softening. Separately, Republican state attorneys general criticized the decision, insisting on strict federal prohibition. This internal party tension underscores frustrations with federal overreach into state matters.

Two GOP senators, Ted Budd of North Carolina and James Lankford of Oklahoma, filed an amendment to a Fiscal Year 2026 DOJ funding bill. The measure aims to block the Justice Department from executing Trump’s order. Though its fate remains uncertain, it signals Senate resistance. The DEA notes a rescheduling appeal process persists despite the executive push. These efforts highlight conservative priorities: law enforcement primacy and skepticism of medical claims lacking full consensus.

Pragmatic Benefits Align with Conservative Principles

Reclassification delivers tax relief to state-legal cannabis businesses barred from deductions under Section 280E, fostering economic growth without federal legalization. Cannabis stocks surged on the news, drawing investment long deterred by Schedule I stigma. Medical research expands, potentially yielding FDA-approved treatments for patients. Industry leader Vince C. Ning of Nabis praised the step for accelerating science and easing burdens, while eyeing interstate commerce next. Ohio State experts warn of transition confusion but affirm transformative potential.

This bipartisan evolution—initiated under Biden, completed under Trump—resolves a 50-year federal-state clash since 1970. It upholds recreational prohibition federally, protecting communities from abuse risks conservatives emphasize. Patients gain access to full-spectrum CBD, prioritizing individual health over blanket bans. Both sides of the aisle share distrust of deep state delays; Trump’s action cuts red tape, empowering states and markets. Yet GOP pushback reveals rifts, as elites in D.C. prioritize control over practical reform benefiting everyday Americans chasing the dream through hard work.